Oculis Shares Rise After Therapy Receives Breakthrough Designation from FDA

Dow Jones

Jan 06

By Connor Hart

Shares of Oculis climbed after the company said its treatment for optic neuritis, or inflammation of the optic nerve that causes blurred vision and eye pain, received a breakthrough therapy designation from the Food and Drug Administration.

The stock rose 13%, to $22.29, in premarket trading Tuesday. Through Monday's close, the stock has gained 8.4% over the past year.

The biopharmaceutical company said that its treatment, Privosegtor, has the potential to become the first neuroprotective therapy for optic neuropathies.

The drug's breakthrough designation is based on results from a recent mid-stage trial that showed the treatment delivered substantial improvement in low-contrast visual acuity, along with consistent anatomical and biological benefits compared with placebo, according to Oculis.

Chief Executive Riad Sherif said the designation underscores the drug's potential as a first-of-its-kind neuroprotective therapy for people living with optic neuritis. "Oculis is uniquely positioned to reshape the treatment landscape in areas with substantial unmet needs, and 2026 is shaping up to be a milestone-rich year across our late-stage portfolio," he added.

Write to Connor Hart at connor.hart@wsj.com

(END) Dow Jones Newswires

January 06, 2026 06:52 ET (11:52 GMT)

Copyright (c) 2026 Dow Jones & Company, Inc.

At the request of the copyright holder, you need to log in to view this content

LOGIN / SIGN UP

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

1
2
3
4
5
6
7
8
9
10

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/2601891218"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2601891218\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2601891218?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-01-06 19:52","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2601891218","market":"sg","top_or_hot":-1,"title":"Oculis Shares Rise After Therapy Receives Breakthrough Designation from FDA","media":"Dow Jones","content":"<font class=\"NormalMinus1\" face=\"Arial\">\n<p>\n  By Connor Hart \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  Shares of <a href=\"https://laohu8.com/S/OCS\">Oculis</a> climbed after the company said its treatment for optic neuritis, or inflammation of the optic nerve that causes blurred vision and eye pain, received a breakthrough therapy designation from the Food and Drug Administration. \n</p>\n<p>\n  The stock rose 13%, to $22.29, in premarket trading Tuesday. Through Monday's close, the stock has gained 8.4% over the past year. \n</p>\n<p>\n  The biopharmaceutical company said that its treatment, Privosegtor, has the potential to become the first neuroprotective therapy for optic neuropathies. \n</p>\n<p>\n  The drug's breakthrough designation is based on results from a recent mid-stage trial that showed the treatment delivered substantial improvement in low-contrast visual acuity, along with consistent anatomical and biological benefits compared with placebo, according to Oculis. \n</p>\n<p>\n  Chief Executive Riad Sherif said the designation underscores the drug's potential as a first-of-its-kind neuroprotective therapy for people living with optic neuritis. \"Oculis is uniquely positioned to reshape the treatment landscape in areas with substantial unmet needs, and 2026 is shaping up to be a milestone-rich year across our late-stage portfolio,\" he added. \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  Write to Connor Hart at connor.hart@wsj.com \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  January 06, 2026 06:52 ET (11:52 GMT)\n</p>\n<p>\n  Copyright (c) 2026 Dow Jones &amp; Company, Inc.\n</p>\n</font>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Oculis Shares Rise After Therapy Receives Breakthrough Designation from FDA</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nOculis Shares Rise After Therapy Receives Breakthrough Designation from FDA\n</h2>\n\n<h4 class=\"meta\">\n\n\n<div class=\"head\" \">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Dow Jones </p>\n<p class=\"h-time\">2026-01-06 19:52</p>\n</div>\n\n</div>\n\n\n</h4>\n\n</header>\n<article>\n<font class=\"NormalMinus1\" face=\"Arial\">\n<p>\n  By Connor Hart \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  Shares of <a href=\"https://laohu8.com/S/OCS\">Oculis</a> climbed after the company said its treatment for optic neuritis, or inflammation of the optic nerve that causes blurred vision and eye pain, received a breakthrough therapy designation from the Food and Drug Administration. \n</p>\n<p>\n  The stock rose 13%, to $22.29, in premarket trading Tuesday. Through Monday's close, the stock has gained 8.4% over the past year. \n</p>\n<p>\n  The biopharmaceutical company said that its treatment, Privosegtor, has the potential to become the first neuroprotective therapy for optic neuropathies. \n</p>\n<p>\n  The drug's breakthrough designation is based on results from a recent mid-stage trial that showed the treatment delivered substantial improvement in low-contrast visual acuity, along with consistent anatomical and biological benefits compared with placebo, according to Oculis. \n</p>\n<p>\n  Chief Executive Riad Sherif said the designation underscores the drug's potential as a first-of-its-kind neuroprotective therapy for people living with optic neuritis. \"Oculis is uniquely positioned to reshape the treatment landscape in areas with substantial unmet needs, and 2026 is shaping up to be a milestone-rich year across our late-stage portfolio,\" he added. \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  Write to Connor Hart at connor.hart@wsj.com \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  January 06, 2026 06:52 ET (11:52 GMT)\n</p>\n<p>\n  Copyright (c) 2026 Dow Jones &amp; Company, Inc.\n</p>\n</font>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"OCS","symbol_name":"Oculis","start_time":0,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","article_id":"2601891218","we_media_id":"106","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2601891218","pubTimestamp":1767700320,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Dow Jones","introduction":"Dow Jones publishes the world’s most trusted business news and financial information in a variety of media.","home_visible":0,"id":"106","head_image":"https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99"},"summary":"Shares of Oculis climbed after the company said its treatment for optic neuritis, or inflammation of the optic nerve that causes blurred vision and eye pain, received a breakthrough therapy designation from the Food and Drug Administration.The stock rose 13%, to $22.29, in premarket trading Tuesday. Through Monday's close, the stock has gained 8.4% over the past year.The biopharmaceutical company said that its treatment, Privosegtor, has the potential to become the first neuroprotective therapy for optic neuropathies.The drug's breakthrough designation is based on results from a recent mid-stage trial that showed the treatment delivered substantial improvement in low-contrast visual acuity, along with consistent anatomical and biological benefits compared with placebo, according to Oculis.Chief Executive Riad Sherif said the designation underscores the drug's potential as a first-of-its-kind neuroprotective therapy for people living with optic neuritis. \"Oculis is uniquely positioned t","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"OCS":"Oculis","BK4007":"制药"},"translate_title":"Oculis疗法获得FDA突破性认定后股价上涨","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"OCS":1.5},"content_text":"By Connor Hart \n\n\n \n\n\n  Shares of Oculis climbed after the company said its treatment for optic neuritis, or inflammation of the optic nerve that causes blurred vision and eye pain, received a breakthrough therapy designation from the Food and Drug Administration. \n\n\n  The stock rose 13%, to $22.29, in premarket trading Tuesday. Through Monday's close, the stock has gained 8.4% over the past year. \n\n\n  The biopharmaceutical company said that its treatment, Privosegtor, has the potential to become the first neuroprotective therapy for optic neuropathies. \n\n\n  The drug's breakthrough designation is based on results from a recent mid-stage trial that showed the treatment delivered substantial improvement in low-contrast visual acuity, along with consistent anatomical and biological benefits compared with placebo, according to Oculis. \n\n\n  Chief Executive Riad Sherif said the designation underscores the drug's potential as a first-of-its-kind neuroprotective therapy for people living with optic neuritis. \"Oculis is uniquely positioned to reshape the treatment landscape in areas with substantial unmet needs, and 2026 is shaping up to be a milestone-rich year across our late-stage portfolio,\" he added. \n\n\n \n\n\n  Write to Connor Hart at connor.hart@wsj.com \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  January 06, 2026 06:52 ET (11:52 GMT)\n\n\n  Copyright (c) 2026 Dow Jones & Company, Inc.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"productRelease","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":true,"code":"91000000","status":"200"}}}